Your browser doesn't support javascript.
loading
Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with BRCA pathogenic variant.
Kimura, Ayako; Nakagomi, Hiroshi; Inoue, Masayuki; Oka, Tomomi; Hirotsu, Yosuke; Amemiya, Kenji; Mochizuki, Hitoshi; Oyama, Toshio; Omata, Masao.
Affiliation
  • Kimura A; Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.
  • Nakagomi H; Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.
  • Inoue M; Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.
  • Oka T; Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.
  • Hirotsu Y; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Amemiya K; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Mochizuki H; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Oyama T; Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Omata M; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Int Cancer Conf J ; 13(3): 193-198, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38962040
ABSTRACT
A 61-year-old woman with BRCA2 pathogenic variant had been treated for 20 years and showed dynamic changes in the genomic profile of her metachronous bilateral breast cancer and metastases. She underwent right breast conservation surgery at age 42-Genome 1, lung metastasis and left axillary lymph node metastasis at age 51, partial excision under local anesthesia for left breast cancer at age 53-Genome 2, left axillary lymph node dissection was added 6 month later-Genome 3. Then, olaparib was administered, and subsequently, left mastectomy was performed for the recurrence of left breast cancer at age 59-Genome 4. Genomic profile of the tumor was analyzed at four points (Genome 1-3 were analyzed by in house breast cancer panel, and Genome 4 was analyzed by Foundation One CDx). Two interesting findings emerged from these analyses. First, the genomic profile revealed that the left axillary lymph node metastasis, considered histologically from right breast cancer, was a metastasis from the left breast cancer. The second finding is that as the disease progressed, mutation profile became more diverse. The profile of the left breast cancer removed after olaparib and other treatments showed reversion mutation of BRCA2 and was diagnosed as tumor mutation burden high. Subsequent response to pembrolizumab was favorable.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int Cancer Conf J Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int Cancer Conf J Year: 2024 Document type: Article